Kahn David A
KAHN: Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY.
J Psychiatr Pract. 2019 Jul;25(4):308-312. doi: 10.1097/PRA.0000000000000404.
Gabapentin is an anticonvulsant medication with an indication from the US Food and Drug Administration for use in partial onset seizures and postherpetic neuralgia in the United States. Currently, gabapentin is only classified as a controlled substance subject to stricter prescribing and distributing regulations in certain states, as opposed to pregabalin, an anticonvulsant with a similar mechanism of action which is a considered a Schedule V medication under federal law. Gabapentin shares a structural similarity to pregabalin, and several case reports have suggested that gabapentin has a similar propensity for abuse. The mechanisms of the gabapentin reward pathway, addiction, and withdrawal, however, are not well known. This case report describes a patient with long-term polysubstance abuse and new onset gabapentin dependence and demonstrates the need for increased surveillance of gabapentin prescribing.
加巴喷丁是一种抗惊厥药物,在美国获美国食品药品监督管理局批准用于治疗部分性发作和带状疱疹后神经痛。目前,加巴喷丁仅在某些州被列为受更严格处方和分发规定管制的物质,这与作用机制相似的抗惊厥药物普瑞巴林不同,普瑞巴林根据联邦法律被列为V类药物。加巴喷丁与普瑞巴林在结构上有相似之处,一些病例报告表明加巴喷丁也有类似的滥用倾向。然而,加巴喷丁的奖赏途径、成瘾及戒断机制尚不清楚。本病例报告描述了一名长期滥用多种物质且新出现加巴喷丁依赖的患者,并表明需要加强对加巴喷丁处方的监测。